Astrazeneca Luxembourg
AstraZeneca Luxembourg, a subsidiary of the global biopharmaceutical giant AstraZeneca, is headquartered in Luxembourg (LU) and operates extensively across Europe and beyond. Founded in 1999, the company has established itself as a leader in the pharmaceutical industry, focusing on innovative medicines in areas such as oncology, cardiovascular, renal, and respiratory diseases. AstraZeneca is renowned for its commitment to research and development, with a robust pipeline of unique therapies that address unmet medical needs. The company’s core products, including groundbreaking treatments like Tagrisso and Farxiga, exemplify its dedication to advancing healthcare. With a strong market position, AstraZeneca Luxembourg continues to achieve notable milestones, contributing significantly to global health and improving patient outcomes.
DitchCarbon Score
How does Astrazeneca Luxembourg's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astrazeneca Luxembourg's score of 98 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AstraZeneca Luxembourg currently does not report specific carbon emissions data, as no emissions figures are available for the most recent year. However, the company is part of the AstraZeneca PLC corporate family, which has established significant climate commitments and initiatives. As a current subsidiary of AstraZeneca PLC, AstraZeneca Luxembourg inherits its climate strategies and targets. AstraZeneca PLC has set ambitious goals to reduce its carbon footprint, including commitments to the Science Based Targets initiative (SBTi) and participation in various climate initiatives such as CDP, RE100, and the Race to Zero campaign. These initiatives aim to drive substantial reductions in greenhouse gas emissions across all scopes, particularly focusing on Scope 1 and Scope 2 emissions, while also addressing Scope 3 emissions through supply chain engagement. While specific reduction targets for AstraZeneca Luxembourg are not detailed, the overarching commitments from AstraZeneca PLC reflect a strong dedication to sustainability and climate action. The company is actively working towards achieving net-zero emissions by 2025 for its global operations, which includes a focus on renewable energy and energy efficiency improvements. In summary, while AstraZeneca Luxembourg does not provide specific emissions data, it aligns with the robust climate commitments and reduction initiatives set forth by its parent company, AstraZeneca PLC, demonstrating a proactive approach to addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astrazeneca Luxembourg is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
